PMC-403 / PharmAbcine - LARVOL DELTA

PMC403-A01: Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=17 | Completed | Sponsor: PharmAbcine | Recruiting ➔ Completed | N=36 ➔ 17 | Trial primary completion date: May 2024 ➔ Aug 2025

Enrollment change • Trial completion • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

[Press Release] PharmAbcine Successfully Completes Phase 1 Clinical Trial of TIE2-Targeting Antibody PMC-403 (PharmAbcine Press Release) - "PharmAbcine confirmed receipt of the final Clinical Study Report (CSR) on December 17, 2025. Based on the integrated analysis, PMC-403 demonstrated favorable tolerability and a predictable safety profile, with no dose-limiting toxicities (DLTs) or major safety concerns observed up to the maximum planned dose, following both single and multiple administrations. In addition, functional and anatomical efficacy-related endpoints were generally maintained relative to baseline across most dose levels and assessment time points, with modest improvement trends observed in selected dose cohorts...The company plans to advance PMC-403 into subsequent stages of clinical development."

First-in-human • P1 data • Trial completion • Wet Age-related Macular Degeneration

PharmAbcine Announces Safety Approval for 4mg Single-dose Cohort in Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration (PRNewswire) - "PharmAbcine...announced that its TIE2-activating antibody candidate, PMC-403, has received unanimous safety approval from the Safety Review Committee (SRC) for the 4mg single ascending dose (SAD) cohort in its Phase 1 clinical trial for neovascular age-related macular degeneration (nAMD). The Company is now preparing to begin enrollment for the 4mg multiple ascending dose (MAD) cohort....This Phase 1 trial targets patients with neovascular AMD who no longer respond to anti-VEGF standard therapies. The safety and tolerability of the 4mg single dose were successfully confirmed, laying the groundwork for advancing to the multiple-dosing phase."

DSMB • Trial status • Wet Age-related Macular Degeneration

PharmAbcine's Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg (PRNewswire) - "PharmAbcine...announced today the decision to advance PMC-403, its candidate treatment for neovascular age-related macular degeneration (nAMD), to the fourth single-dose group of 4mg and first multiple-dose group of 3mg in Phase 1 clinical trial....This Phase 1 trial targets patients with neovascular age-related macular degeneration who are no longer responding to anti-VEGF standard therapeutics. With the SRC's decision, the trial will advance to the highest single dose cohort (4mg) and the first multiple ascending dose cohort (3mg), potentially providing more advanced data from this Phase 1 study."

Trial status • Wet Age-related Macular Degeneration

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: PharmAbcine | Not yet recruiting ➔ Recruiting

Enrollment open • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CRP

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD (PRNewswire-Asia) - "PharmAbcine...announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company's novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration). The study, consisting of single ascending-dose cohort and multiple ascending-dose cohort, has dosed the first of 36 planned study subjects. The Phase I clinical trial, an open-label, multi-center, single and multiple ascending-dose study, is currently enrolling patients at multiple hospitals in South Korea, including Seoul National University Bundang Hospital."

Trial status • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Wet Age-related Macular Degeneration

Study to Assess Safety and Tolerability of PMC-403 in Subjects With Neovascular Age-related Macular Degeneration (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: PharmAbcine

New P1 trial • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration • CRP